Xifaxan sales

Xifaxan does not have a biosimilar risk because rifaximin is a small-molecule drug. Its principal competitive threat is an abbreviated new drug application, or ANDA, for generic rifaximin tablets. How much does Xifaxan generate in sales? Bausch reports Xifaxan as a major contributor to Salix revenue. Annual Sales of Xifaxan reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Annual Sales of Xifaxan, Rifacol, Fatroximin, Rifaximin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. XIFAXAN tablets for oral administration are film-coated and contain 200 mg or 550 mg of rifaximin. Inactive ingredients: Each 200 mg tablet contains colloidal silicon dioxide, disodium edetate, glycerol palmitostearate, hypromellose, microcrystalline cellulose, propylene glycol, red iron oxide, sodium starch glycolate, talc, and titanium dioxide. Each 550 mg tablet contains colloidal silicon … Xifaxan® drove sales in the fourth quarter with 16% growth and was the primary contributor to segment growth for the full year. Branded XIFAXAN sales are projected to continue a steep decline. The overall rifaximin market is now largely driven by generic competition, leading to significant price erosion. Alternative therapies for both hepatic encephalopathy and irritable bowel syndrome with diarrhea remain competitive. Frequently Asked Questions 2016 – Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan ® And Relistor ® – Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit – Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor ® Tablets Key Takeaways: Rifaximin Market USD 73 million in sales were recorded in 2025, signalling broad clinician acceptance for hepatic encephalopathy and IBS‑D. The market is set to reach USD 110 million by 2034, buoyed by new therapeutic approvals and expanding generic capacity in Asia‑Pacific. The indication push comes as Xifaxan is gaining market share, thanks to the field sales team—expanded by 250 reps last year—targeting primary care physicians, Papa said. The ruling ensures Bausch's XIFAXAN® retains market exclusivity until at least June 29, 2028, when Teva's generic enters the market. XIFAXAN® generated $1.2 billion in global sales in 2024, with IBS-D accounting for over 60% of U.S. prescriptions. RIFAXIMIN (ri FAX i men) treats diarrhea caused by bacteria. It may also be used to treat irritable bowel syndrome (IBS) with diarrhea. It can be used to prevent hepatic encephalopathy, a condition where the liver does not clear toxins from the body. It works by killing or preventing the growth of bacteria in your intestines that make toxins. It belongs to a group of medications called … BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. Rifaximin, sold under the trade name Xifaxan among others, is an antibiotic used to treat traveler"s diarrhea, irritable bowel syndrome, and hepatic encephalopathy. The Rifaximin market represents a specialized segment within the broader pharmaceutical landscape, primarily focused on the production, distribution, and clinical application of rifaximina semi synthetic, broad spectrum antibiotic derived from rifamycin. Annual Sales of Rifaximin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Yet, selling Salix would strip out one of Valeant's most attractive and best-selling assets, the irritable-bowel syndrome treatment Xifaxan (rifaximin). Although the drug has performed worse than expected this year — partly due to sales force turmoil — it still brought in $200 million in Q2 sales, more than any other drug in Valeant's … Xifaxan (rifaximin) is a prescription antibiotic used to treat irritable bowel syndrome with diarrhea (IBS-D), traveler's diarrhea caused by certain strains of E. coli, and to reduce the risk of recurrent hepatic encephalopathy in adults with liver disease. Rifaximin, sold under the trade name Xifaxan among others, is an antibiotic used to treat traveler"s diarrhea, irritable bowel syndrome, and hepatic encephalopathy. RIFAXIMIN (ri FAX i men) treats diarrhea caused by bacteria. It may also be used to treat irritable bowel syndrome (IBS) with diarrhea. It can be used to prevent hepatic encephalopathy, a condition where the liver does not clear toxins from the body. It works by killing or preventing the growth of bacteria in your intestines that make toxins. It belongs to a group of medications called … Now that Valeant's $10 billion talks to sell its Salix unit to Takeda have reportedly fallen through, the company is taking matters into its own hands with a "significant" GI sales force … Earlier this month, the new Valeant chief attributed Xifaxan's slump to "sales force disruption" over the past 12 months–something the company says it's been working to address by inserting … Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales. Compare generic Xifaxan (rifaximin) 550 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for generic Xifaxan (rifaximin). Discounts up to 80% off the retail price. XIFAXAN, Bausch Health's rifaximin product, is one of the largest gastrointestinal specialty drugs in the U.S. market. Its commercial base is concentrated in two approved indications: reduction in hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. U.S. sales have continued to grow despite long-standing generic challenges, supported by high patient … Sales growth was driven by Xifaxan® and Relistor®, partially offset by net pricing pressures for Trulance® and certain non-promoted products. International Segment International segment reported revenues were $265 million for the first quarter of 2024, compared with $247 million for the first quarter of 2023, an increase of $18 million, or 7%. Market By Application Analysis Hepatic Encephalopathy led rifaximin tablets revenues in 2025, capturing nearly 60% of the global share In 2025, Hepatic Encephalopathy generated USD 862.77 Million and accounted for 59.5% of the global rifaximin tablets market, representing approximately the majority of category sales. The Rifaximin market was valued at $2.1 billion in 2025 and is projected to reach $5.4 billion by 2034, growing at a CAGR of 11.4%. XIFAXAN, Bausch Health's liver disease treatment with top medical recommendations, enters CMS drug pricing negotiations under Inflation Reduction Act for 2027 implementation. Xifaxan supply disruptions are affecting patients nationwide. Check current availability, find pharmacies with stock near you, and explore your options. Relistor and Trulance revenues were up 9% each. Xifaxan 550 mg tablets are indicated for the reduction in the risk of overt hepatic encephalopathy recurrence and the treatment of IBS-D in adults. The Rifaximin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. Transfer your prescription for XIFAXAN 550 MG TAB on Amazon Pharmacy. FREE SHIPPING for Prime members. Key Takeaways: Rifaximin Market USD 73 million in sales were recorded in 2025, signalling broad clinician acceptance for hepatic encephalopathy and IBS‑D. The market is set to reach USD 110 million by 2034, buoyed by new therapeutic approvals and expanding generic capacity in Asia‑Pacific. Get your Xifaxan 550 mg Tablets from HealthWarehouse, your trusted online pharmacy. We offer affordable healthcare products that get delivered right to your door. Compare Xifaxan 550 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for Xifaxan. Discounts up to 80% off the retail price. Compare Xifaxan prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. Global Rifaximin Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031 The global Rifaximin market size was US$ 75 million in 2024 and is forecast to a readjusted size of US$ 102 million by 2031 with a CAGR of 4.6% during the forecast period 2025-2031. Contradiction Point 1 Xifaxan Sales Peak Year and EBITDA Trajectory Contradiction on whether 2026 or 2025 is the peak sales year for Xifaxan and the expected EBITDA dip in 2027. Jeevan (Truist) – Jeevan (Truist) 2026Q1: Volume is anticipated to remain consistent with current trends. – [Jean-Jacques Charhon] (CFO)